Join us for our fourth episode of the new Myeloma Crowd Research Initiative of the proposals under consideration for the MCRI patient-led funding initiative. Dr. Bruno Paiva, PhD, is a multiple myeloma researcher from the University of Navarra Spain specializing in minimal residual disease (MRD) detection using flow cytometry. What does the newer MRD testing mean for high-risk patients? Dr. Paiva will describe his new study to find more clues and therefore better treatments for high-risk patients.
Sorry we couldn't complete your registration. Please try again.
You must accept the Terms and conditions to register